Autologous bone marrow mononuclear cells [presumed to include haematopoietic stem cells (HSCs)] are a standard of care for blood-related diseases but have failed globally to regenerate other organs. It is increasingly becoming evident that human pluripotent stem cells (PSCs) including embryonic stem cells (hES) and induced pluripotent stem cells (iPS) tend to differentiate into their foetal counterparts and have resulted in the formation of organoids which are perfect to study early embryonic development, but their ability to regenerate adult organs remains questionable. In contrast, very small embryonic-like stem cells (VSELs) are PSCs that exist in adult organs, express pluripotent markers, differentiate into cells of all three germ layers in vitro, are mobilized to various organs under conditions of stress/disease, and give rise to tissue-committed progenitors that maintain lifelong homeostasis. Thus, the research focus of our group has shifted from hES cells to VSELs to develop strategies wherein one can manipulate endogenous VSELs and their somatic microenvironment to achieve regeneration, to understand disease pathology and also their role in cancer initiation.

We initiated our research on stem cells with a focus on hES cells and derived two well-characterized hES cell lines KIND1 and KIND2 on human feeder layers and have now been adapted to expand under feeder-free conditions. Both the cell lines showed good propensity to differentiate into endoderm and mesoderm, and our efforts were focused on their differentiation into pancreatic and tripotent cardiac progenitors. A pre-clinical study using KIND1-derived pancreatic progenitors in streptozotocin-treated diabetic mice showed that mice transplanted with a microcapsule containing hES-derived pancreatic progenitors were capable of regulating blood sugar levels for up to 90 days compared to control streptozotocin-treated diabetic mice that did not survive beyond 30 days (unpublished observations).

While working on hES cells, the importance of transcription factors, especially nuclear OCT-4 was realized which is crucial for maintaining pluripotent state of a stem cell. Nuclear OCT-4 positive VSELs were reported by our group in adult human testes and ovaries, and were recently reviewed. Both hES cells and VSELs are PSCs wherein hES cells are derived from inner cell mess (ICM) of blastocyst-stage embryo and VSELs are postulated to be an overlapping population of the migrating primordial germ cells (PGCs) that settle down in various adult organs during early development. Ratajczak et al recently reported reversal of quiescent state of VSELs by treating with histone deacetylase inhibitor valproic acid and nicotinamide in vitro. They could expand VSELs ex vivo by about 10^3 folds in chemically defined medium after culture for 1-2 months in the presence of growth factors and hormones including follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Cells with pluripotent properties have been described in adult organs by multiple groups (Fig. 1) and also named differently such as spore-like cells, multipotent adult progenitor cells (MAPC), amniotic fluid stem cells (AFSC), marrow-isolated adult multilineage-inducible cells (MIAMI), VSELs, or multi-lineage differentiation stress-enduring stem cells (MUSE). However, these comprise a single stem cell population in a ‘dark room’ being examined through different key holes by various investigators. It has been suggested that the controversy surrounding isolation protocols for VSELs needs to be sorted out by organizing workshops. These stem cells express pluripotent transcription factors and also exhibit the ability to differentiate into three germ layers. Transcription factor OCT-4 has alternately spliced
 isoforms and it is OCT-4A which is responsible for pluripotent state and not cytoplasmic OCT-4B. Our group has demonstrated that VSELs express nuclear OCT-4A whereas the progenitors express cytoplasmic OCT-4B that eventually degrades as cells differentiate further.

Human ES and iPS cells exist only in culture and have been described as tissue culture artefacts in literature. Human ES cells are understood to exist in ‘primed’ (flattened monolayer colony morphologies, FGF and Activin/nodal signalling pathways, expressions of SSEA4, TRA 1-60 and TRA-1-81, X chromosome inactivation in females) and ‘naïve’ (small, round or dome-shaped colony morphologies, LIF and BMP4 signalling pathways, SSEA-1 expression and two active X chromosomes in female) states. Attempts are being made to convert ‘primed’ hES cells into ‘naïve’ state as it enhances their ability to differentiate. Thus, the scientific community is possibly going through a phase of denial regarding the differentiation potential of ES/iPS cells into desired cell types (which remains highly inefficient) and has diverted research efforts on understanding ‘naïve’ and ‘primed’ states of hES cells and also of research efforts are focused on organoids developed in vitro from ES/iPS cells.

Rather than moving in these basic research directions, we have diverted our research efforts on endogenous, pluripotent VSELs in adult organs to exploit their regenerative/translational potential. Differentiation potential of hES cells and VSELs are compared below using two examples (i) regenerating a diabetic pancreas, and (ii) making ‘synthetic’ gametes. VSELs are also compared to adult stem cells.

**Regenerating a diabetic pancreas**

Work done in this field using different kinds of stem cells has been recently reviewed. A US-Food and Drug Administration-approved clinical trial is ongoing by ViaCyte, USA to treat type 1 diabetes mellitus (DM) using pancreatic progenitors derived from hES cells. No outcome results have come so far. It has been realized over time that hES as well as iPS cells tend to give rise to their foetal counterparts and thus may not be efficient enough to behave like or regenerate adult organs. In contrast, VSELs actively regenerate adult mouse pancreas (and differentiate into all cell types) after >80 per cent is removed surgically. We have also shown that VSELs exist in adult pancreas and that their dysfunction with age may lead to both type 2 DM and pancreatic cancer. Flow cytometry studies show that LIN-/CD45-/SCA-1+ VSELs increase in numbers in a diabetic pancreas and can regenerate a diabetic pancreas after partial pancreatectomy (unpublished data from our laboratory). It is known that if >80 per cent of diabetic pancreas is surgically removed, it regenerates back to normal state and we have demonstrated that VSELs bring about this regeneration. Thus, compared to >90 day survival of diabetic mice which were transplanted hES cells-derived pancreatic progenitors...
It is an expensive affair to make hES cells clinical grade and then produce progenitor cells in cGMP facility for clinical use. The first clinical trial by Geron using hES cells for spinal cord injury (http://www.nytimes.com/2011/11/15/business/geron-is-shutting-down-its-stem-cell-clinical-trial.html?r=0) was stopped due to financial constraints. The first clinical trial using iPS cells is on hold at present for genetic reasons, and both genetic instability and presence of mutations in mitochondrial DNA in iPS cells have put a big question mark on their potential for regenerative medicine. VSELs are endogenous PSCs which have no associated immunological issues nor impose any risk of teratoma formation (Table). Besides regenerating adult pancreas, VSELs are also involved in regeneration of liver, lung and neurons in various animal models.

**Making gametes from hES and iPS cells versus VSELs**

Making gametes from stem cells to help infertile couples is considered to be the highest goal of regenerative medicine, but obtaining human gametes from ES/iPS cells is still a thing of future. The major hurdle being to convert hES/iPS cells into PGCs-like cells (PGCLCs). PGCs are precursors and spontaneously differentiate into gametes (Fig. 2). Success achieved and gametes have been differentiated from mouse ES/iPS cells but the process remains inefficient and fraught with safety issues. Being similar to PGCs, VSELs spontaneously differentiate into oocyte-like structures and sperm in vitro. We have recently reported that even mouse bone marrow VSELs can differentiate into germ cells in vitro. Choosing between ES/iPS/VSELs to make gametes has been debated.

**VSELs compared to adult stem cells**

VSELs also score better compared to adult stem cells (Table) including HSCs because HSCs are committed progenitors that arise from the VSELs. Very small, CD45 negative VSELs have been reported to differentiate into CD45 positive HSCs when cultured on OP9 feeder layer. A review on VSELs discussing their developmental link to PGCs and that these are most primitive stem cells in the haematopoietic system capable of giving rise to HSCs, MSCs and EPCs has been recently published.

| VSELs compared to hES & iPS cells |
|-----------------------------------|
| Unlike hES cells, endogenous VSELs will not face immunological issues. Induced pluripotent stem cells harbour mutations in both genomic and mitochondrial DNA and thus cannot be an ideal starting material to make gametes. Also, due to safety concerns of using autologous iPS cells in the first clinical trial, allogeneic use of iPS cells is being considered for clinical applications - that will have associated immunological issues. |
| Compared to ES & iPS cells which give rise to foetal counterparts and form organoids in vitro, VSELs easily regenerate adult organs. |
| Unlike hES & iPS cells, use of VSELs for regenerative medicine has no associated risk of tumour formation. |

**In the haematopoietic system, VSELs are pluripotent stem cells with regenerative potential and not HSCs/MSCs.**

VSELs express nuclear OCT-4 whereas HSCs/MSCs express cytoplasmic OCT-4. Thus, VSELs are the true pluripotent stem cells whereas HSCs/MSCs are committed progenitors.

**VSELs, very small embryonic-like stem cells; hES, human embryonic stem; iPS, induced pluripotent stem; HSCs, haematopoietic stem cells; MSCs, mesenchymal stem cells**

**Table. VSELs compared to hES, iPS, HSCs and MSCs for regenerative medicine**

| VSELs compared to hES, iPS, HSCs and MSCs for regenerative medicine |
|---------------------------------------------------------------|
| VSELs |
| Unlike hES cells, endogenous VSELs will not face immunological issues. Induced pluripotent stem cells harbour mutations in both genomic and mitochondrial DNA and thus cannot be an ideal starting material to make gametes. Also, due to safety concerns of using autologous iPS cells in the first clinical trial, allogeneic use of iPS cells is being considered for clinical applications - that will have associated immunological issues. |
| Compared to ES & iPS cells which give rise to foetal counterparts and form organoids in vitro, VSELs easily regenerate adult organs. |
| Unlike hES & iPS cells, use of VSELs for regenerative medicine has no associated risk of tumour formation. |

**Fig. 2.** Making human gametes from pluripotent stem cells. It is technically difficult to differentiate ES/iPS cells into primordial germ cells (PGCs) as it involved lot of epigenetic changes which may be difficult to replicate in vitro. VSELs are developmentally linked to PGCs which are natural precursors to the gametes. Thus VSELs spontaneously differentiate into gametes.
Trials using autologous bone marrow mononuclear cells (presumed to include HSCs) have failed globally because HSCs are committed progenitors and not pluripotent as reported earlier and their ability to trans-differentiate remains questionable. As a result, HSCs will help recolonize bone marrow during blood-related diseases and have been greatly successful during bone marrow transplantation but do not possess the ability to regenerate other organs. Autologous adipose tissue derived stem cells have resulted in blindness in patients with age-related macular degeneration. Developing therapeutic approaches using stem cells and associated risks and benefits have been recently discussed by a group from US FDA. They stressed that rather than rushing to the clinics, our approach to exploit clinical potential of stem cells should be based on sound evidence. VSELs isolated from human cord blood and bone marrow can differentiate into cells of all three germ layers. Our group has also demonstrated that VSELs isolated from 5-flurouracil (5-FU)-treated mouse bone marrow can differentiate into progenitors of three germ layers (neuronal, pancreatic and cardiac) and also give rise to HSCs and germ cells in vitro. However, the clinical potential of VSELs remains to be tested since these have been unknowingly discarded during processing of samples for transplantation. VSELs in the haematopoietic system survive total body irradiation and treatment with 5-FU and increase in numbers as evidenced by BrdU uptake, thus suggesting an important role played in bone marrow regeneration.

**Ontogeny of embryonic stem (ES) cells and VSELs explains differences in their regenerative potential**

The underlying reason for better potential of VSELs over ES cells is based on their ontogeny. PSCs are first established in the ICM of pre-implantation blastocyst, and after implantation, ICM transitions into post-implantation epiblast cells. During gastrulation, some of the post-implantation epiblast cells are specified as PGCs which retain pluripotent state. ES cells are derived from ICM of blastocyst-stage embryo whereas VSELs are overlapping with migrating PGCs which appear for the first time in epiblast-stage embryo. The ICM and post-implantation epiblast cells are distinct, based on the differences in their gene expression profiles, epigenetic status and differentiation capacity. PGCs migrate along the dorsal ridge to the gonadal ridge, and while the genetic material of parents is maintained, their epigenome undergoes extensive reprogramming including demethylation of DNA (at CpG islands, transcription start sites, gene bodies and surrounding intergenic regions), histone modifications, expression of epigenetic modifiers and chromatin remodelling on a genome-wide scale. Being equivalent to PGCs, VSELs methylome is distinct compared to ICM from which ES cells are obtained in vitro. Kim et al. have reviewed molecular nature of VSELs in adult organs.

One can differentiate ES cells into pancreatic progenitors based on gene expression and protein profile, but for the cells to acquire similar epigenetic status as adult cells may be difficult to achieve in vitro and this could be the possible bottleneck. Epigenetic status of pancreatic progenitors obtained from hES cells is distinct from adult pancreas, and for the same reason, it is difficult to convert ES/iPS cells into PGCLCs. VSELs are developmentally as well as epigenetically more mature compared to ES cells. Thus, VSELs spontaneously differentiate into gametes and also regenerate adult, diabetic pancreas. Compared to hES cells which are envisaged to provide an alternative replacement for islets alone, VSELs regenerate all pancreatic cell types after partial pancreatectomy.

**Do stem cells initiate cancer?**

Gross and Emanuel discussed that since the launch of ‘War on Cancer’ in 1972, the USA government alone has spent over $100 billion on cancer research, resulting in fundamental discoveries and millions of publications. However, the actual clinical progress has remained modest with cancer mortality decreasing from about 200 to 166 deaths per 100,000 as of 2012. This almost 17 per cent reduction has largely been attributed to 50 per cent decreased smoking over the past 50 yr. It has been postulated that cancers occur due to altered behaviour of VSELs. Why nuclear OCT-4 and other markers CD133, FSH receptors (FSHR) and human chorionic gonadotropin show ubiquitous expression in various kinds of cancers, has been discussed. Whether somatic cells de-differentiation/reprogramming to pluripotent state leads to cancer initiation and explains expression of pluripotent markers in various tumours or pluripotent VSELs existing in various adult organs in small numbers undergo uncontrolled proliferation and get transformed into cancer stem cells has also been discussed.

Thus, it becomes essential that we focus on VSELs to understand how their biology gets affected leading to various diseases, to achieve endogenous regeneration and also to understand cancer initiation. Carefully planned clinical trials need to be undertaken targeting endogenous VSELs for regenerative medicine. Studies
done on VSELS will result in several paradigm shifts in
due course of time.

Highlights of some of the results achieved using
VSELS are listed here: (i) VSELS possibly undergo
asymmetric cell divisions to self-renew and give rise
to the tissue-specific progenitors (HSCs/SSCs/OSCs)
which further undergo symmetric cell divisions and
clonal expansion followed by differentiation into tissue-
specific cell types1,39; (ii) Rather than HSCs, VSELS
have the true potential to differentiate into three germ
layers. HSCs can only differentiate into blood cells.
VSELS are mobilized under various kinds of stress to
restore homeostasis in affected organs17,14; (iii) There
is a need to spin cells at 1000×g to obtain VSELS
rather than widely used speed of 250-270 g.31. Also
after Ficoll-Hypaque density gradient centrifugation,
VSELS settle down with RBCs31 and need to be
enriched (not to be discarded) and used for regenerative
medicine; (iv) VSELS exist in larger numbers during
foetal development40 and are possibly the yet elusive
‘foetal stem cells’.

The use of foetal stem cells for
regenerative medicine is not justified (http://www.
jonline.com/news/opinion/use-of-fetal-tissue-is-
unethical-and-unnecessary-b99357242z1-326513781.
hml) as VSELS exist in adult organs and there is a need
to manipulate them to achieve regeneration; (v) VSELS
regenerate pancreas after partial pancreatectomy14,15;
(vi) Being relatively quiescent, VSELS survive toxic
insults including radiotherapy and chemotherapy1.
These can be targeted to restore gametogenesis41.
There may be no need to bank gonadal tissue prior to
oncotherapy42 and associated legal, ethical and
safety issues could be avoided41; (vii) VSELS are
pluripotent and most primitive stem cells that co-exist
along with spermatogonial stem cells in the testis;
undergo asymmetric cell divisions and can restore
spermatogenesis both in vitro and in vivo30; (viii) VSELS
and OSCs co-exist in ovary surface epithelium and
possibly result in post-natal neo-oogenesis throughout
life44. Age-dependent compromised function of niche
supporting the stem cells results in menopause and
can be manipulated to generate the non-functional
ovary from VSELS39. VSELS have also been
reported in large numbers in human ovarian tumour
tissue45 and mice studies46 suggest that these may be
responsible for formation of leiomyoma that arise
from uterine myometrium. (ix) FSHR are expressed on
VSELS/HSCs/SSCs/OSCs in addition to Sertoli cells
in testis and granulosa cells in the ovary. Thus, FSH
acts directly on the stem cells (in ovary, testis and bone
marrow)1,25,32,37,39,44,47,48.

In view of the reasons discussed above, the
focus of research efforts of our group has shifted
to VSELS for their application in regenerative
medicine.

Deepa Bhartiya
Stem Cell Biology Department,
ICMR- National Institute for Research in
Reproductive Health, Jehangir Merwanji Street,
Parel, Mumbai 400 012,
Maharashtra, India
bhartiyad@nirrh.res.in

Received September 8, 2016

References

1. Bhartiya D, Shaikh A, Anand S, Patel H, Kapoor S,
Sriraman K, et al. Endogenous, very small embryonic-like
stem cells: Critical review, therapeutic potential and a look
ahead. Hum Reprod Update 2016; 23 : 41-76.

2. Kumar N, Hinduja I, Nagvenkar P, Pillai L, Zaveri K,
Mukadam L, et al. Derivation and characterization of two
genetically unique human embryonic stem cell lines on
in-house-derived human feeders. Stem Cells Dev 2009;
18 : 435-45.

3. Nagvenkar P, Pethe P, Pawani H, Telang J, Kumar N, Hinduja I,
et al. Evaluating differentiation propensity of in-house derived
human embryonic stem cell lines KIND-1 and KIND-2.
In Vitro Cell Dev Biol Anim 2011; 47 : 406-19.

4. Pethe P, Nagvenkar P, Bhartiya D. Polycomb group protein
tissue expression during differentiation of human embryonic stem
cells into pancreatic lineage in vitro. BMC Cell Biol 2014;
15 : 18.

5. Pawani H, Nagvenkar P, Pethe P, Bhartiya D. Differentiation
of human ES cell line KIND-2 to yield tripotent cardiovascular
progenitors. In Vitro Cell Dev Biol Anim 2013; 49 : 82-93.

6. Ávila-González D, García-López G, García-Castro IL,
Flores-Herrera H, Molina-Hernández A, Portillo W, et al.
Capturing the ephemeral human pluripotent stem state. Dev Dyn
2016; 245 : 762-73.

7. Ratajczak MZ, Ratajczak JS, Suszynska M, Miller DM, Kucia M,
Shin DM. A novel view of the adult stem cell compartment
from the perspective of a quiescent population of very small
embryonic-like stem cells. Circ Res 2017; 120 : 166-78.

8. Parker GC. Very small embryonic-like stem cells: A scientific
debate? Stem Cells Dev 2014; 23 : 687-8.

9. Hansson MG, Helgesson G, Wessman R, Jaenisch R. Commentary: Isolated stem cells--patentable as
cultural artifacts? Stem Cells 2007; 25 : 1507-10.

10. Willyard C. The boom in mini stomachs, brains, breasts,
kidneys and more. Nature 2015; 523 : 520-2.

11. Bhartiya D. Stem cells to replace or regenerate the diabetic
pancreas: Huge potential & existing hurdles. Indian J Med Res
2016; 143 : 267-74.
12. Schulz TC. Concise Review: Manufacturing of pancreatic endoderm cells for clinical trials in type 1 diabetes. *Stem Cells Transl Med* 2015; 4 : 927-31.

13. Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: Challenges and recent progress. *Nat Rev Genet* 2014; 15 : 82-92.

14. Bhartiya D, Mundekar A, Mahale V, Patel H. Very small embryonic-like stem cells are involved in regeneration of mouse pancreas post-pancreatectomy. *Stem Cell Res Ther* 2014; 5 : 106.

15. Bhartiya D, Patel H. Very small embryonic-like stem cells are involved in pancreatic regeneration and their dysfunction with age may lead to diabetes and cancer. *Stem Cell Res Ther* 2015; 6 : 96.

16. Carpenter MK, Rao MS. Concise review: Making and using clinically compliant pluripotent stem cell lines. *Stem Cells Transl Med* 2015; 4 : 381-8.

17. Garber K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. *Nat Biotechnol* 2015; 33 : 890-1.

18. Reardon S. Mutated mitochondria could hold back stem-cell therapy’s benefits and risks. *Stem Cell Rev Ther* 2015; 4 : 381-8.

19. Tapia N, Schöler HR. Molecular obstacles to clinical translation of iPSCs. *Cell Stem Cell* 2016; 19 : 298-309.

20. Shin DM, Suszynska M, Mierzewska K, Ratajczak J, RatajczakMZ.Very small embryonic-like/stem-cell optimization of isolation protocols: An update of molecular signatures and a review of current *in vivo* applications. *Exp Mol Med* 2013; 45 : e56. doi: 10.1038/emm.2013.117.

21. Zhou Q, Wang M, Yuan Y, Wang X, Fu R, Wan H, et al. Complete meiosis from embryonic stem cell-derived germ cells *in vitro*. *Cell Stem Cell* 2016; 18 : 330-40.

22. Shaikh A, Anand S, Kapoor S, Ganguly R, Bhartiya D. Mouse bone marrow VSELs exhibit differentiation into three embryonic germ lineages and germ & hematopoietic cells in culture. *Stem Cell Rev* 2017; 13 : 202-16.

23. Bhartiya D, Hinduja I, Patel H, Bhilawadikar R. Making gametes from pluripotent stem cells – A promising role for very small embryonic-like stem cells. *Reprod Biol Endocrinol* 2014; 12 : 114.

24. Bhartiya D, Anand S, Patel H. Making gametes from pluripotent stem cells: Embryonic stem cells or very small embryonic-like stem cells? *Stem Cell Investig* 2016; 3 : 57-62.

25. Ratajczak MZ. Why are hematopoietic stem cells so ‘sexy’? on a search for developmental explanation. *Leukemia* 2017; 31 : 1671-7.

26. Ogawa M, LaRue AC, Mehrotra M. Hematopoietic stem cells are pluripotent and not just “hematopoietic”. *Blood Cells Mol Dis* 2013; 51 : 3-8.

27. Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, Pandya HK, Leonard RE 2nd, et al. Vision loss after intravitreal injection of autologous “Stem Cells” for AMD. *N Engl J Med* 2017; 376 : 1047-53.

28. Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. *N Engl J Med* 2017; 376 : 1007-9.

29. Havens AM, Sun H, Shiozawa Y, Jung Y, Wang J, Mishra A, *et al.* Human and murine very small embryonic-like cells represent multipotent tissue progenitors, *in vitro* and *in vivo*. *Stem Cells Dev* 2014; 23 : 689-701.

30. Kucia M, Reca R, Campbell FR, Zuba-Surma E, Majka M, Ratajczak J, *et al.* A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(-)Oct-4(+) stem cells identified in adult bone marrow. *Leukemia* 2006; 20 : 857-69.

31. Bhartiya D, Shaikh A, Nagvenkar P, Kasiviswanathan S, Pethé P, Pawani H, *et al.* Very small embryonic-like stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous stem cell therapy. *Stem Cells Dev* 2012; 21 : 1-6.

32. Shaikh A, Bhartiya D, Kapoor S, Nimkar H. Delineating the effects of 5-fluorouracil and follicle-stimulating hormone on mouse bone marrow stem/progenitor cells. *Stem Cell Rev Ther* 2016; 7 : 59-63.

33. Eguizabal C, Herrera L, De Ohate L, Montserrat N, Hajkova P, Iznipsa Belmonte JC, *et al.* Characterization of the epigenetic changes during human gonadal primordial germ cells reprogramming. *Stem Cells* 2016; 34 : 2418-28.

34. Kim Y, Jeong J, Kang H, Lim J, Heo J, Ratajczak J, *et al.* The molecular nature of very small embryonic-like stem cells in adult tissues. *Int J Stem Cells* 2014; 7 : 55-62.

35. Gross CP, Emanuel EJ. A call for value in cancer research. *JAMA Oncol* 2016; 2 : 11-2.

36. Ratajczak MZ, Shin DM, Kucia M. Very small embryonic/epiblast-like stem cells: A missing link to support the germ line hypothesis of cancer development? *Am J Pathol* 2009; 174 : 1985-92.

37. Bhartiya D. Ubiquitous expression of FSH/LH/hCG receptors, OCT-4, and CD133 in adult organs and cancers reflects novel VSELs biology. *J Reprod Health Med* 2016; 2 : 33-6.

38. Bhartiya D. Do adult somatic cells undergo reprogramming or endogenous pluripotent stem cells get activated to account for plasticity, regeneration and cancer initiation? *Stem Cell Rev* 2017; doi:10.1007/s12015-017-9749-x.

39. Patel H, Bhartiya D. Testicular stem cells express follicle-stimulating hormone receptors and are directly modulated by FSH. *Reprod Sci* 2016; 23 : 1493-508.

40. Zuba-Surma EK, Kucia M, Rui L, Shin DM, Wojakowski W, Ratajczak J, *et al.* Fetal liver very small embryonic/epiblast like stem cells follow developmental migratory pathway of hematopoietic stem cells. *Ann N Y Acad Sci* 2009; 1176 : 205-18.

41. Anand S, Bhartiya D, Sriraman K, Mallick A. Underlying mechanisms that restore spermatogenesis on transplanting healthy niche cells in busulfan treated mouse testis. *Exp Mol Med* 2016; 12 : 114.

42. Bhartiya D. Use of very small embryonic-like stem cells to avoid legal, ethical, and safety issues associated with oncofertility. *JAMA Oncol* 2016; 2 : 689.
44. Bhartiya D, Parte S, Patel H, Sriraman K, Zaveri K, Hinduja I. Novel action of FSH on stem cells in adult mammalian ovary induces postnatal oogenesis and primordial follicle assembly. *Stem Cells Int* 2016; 2016 : 5096596.

45. Virant-Klun I, Stimpfel M. Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer. *Sci Rep* 2016; 6 : 34730.

46. Bhartiya D, James K. Very small embryonic-like stem cells (VSELS) in adult mouse uterine perimetrium and myometrium. *J Ovarian Res* 2017; 10 : 29.

47. Mierzejewska K, Borkowska S, Suszynska E, Suszynska M, Poniewierska-Baran A, Maj M, et al. Hematopoietic stem/progenitor cells express several functional sex hormone receptors-novel evidence for a potential developmental link between hematopoiesis and primordial germ cells. *Stem Cells Dev* 2015; 24 : 927-37.

48. Patel H, Bhartiya D, Parte S, Gunjal P, Yedurkar S, Bhatt M. Follicle stimulating hormone modulates ovarian stem cells through alternately spliced receptor variant FSH-R3. *J Ovarian Res* 2013; 6 : 52.